A phase I study of talotrexin (PT-523) in children and adolescents with recurrent solid tumors or recurrent/refractory leukemias
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2008
At a glance
- Drugs Talotrexin (Primary)
- Indications Leukaemia; Solid tumours
- Focus Adverse reactions
- 18 Jan 2008 Status changed from initiated to withdrawn prior to recruitment.
- 19 Apr 2007 New trial record.